Q-Immune

Cover Block

PUBLIC

Attribute	Details
Name	Q-Immune
Tagline	Predicting cell therapy safety and efficacy using multiplex proteomics and AI for biopharma R&D.
Headquarters	Seattle, United States
Founded	2025
Stage	Pre-Seed
Business Model	SaaS
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)

Links

PUBLIC

This section lists the confirmed digital touchpoints for Q-Immune. The company's public web presence is currently minimal, with a primary website and a privacy policy page serving as the main points of contact. No corporate social media profiles, GitHub repositories, or app store listings were identified in public records.

• Website: https://www.qimmune.com
• Privacy Policy / Terms: https://www.qimmune.com/privacy-policy

Executive Summary

PUBLIC

Q-Immune is a Seattle-based startup applying high-throughput multiplex proteomics and AI to predict the safety and efficacy of CAR-T cell therapies, aiming to de-risk the most expensive phase of biopharma development before clinical trials begin. Founded in 2025, the company is targeting a critical bottleneck in immunotherapy R&D, where the high failure rate and cost of human trials create a clear market for predictive analytics [Life Science Washington Institute, April 2025]. Its core offering is a dual-model business combining a QMI analytics SaaS platform with a wet-lab construct testing service, designed to help pharmaceutical companies benchmark and optimize therapeutic candidates [Life Science Washington Institute, April 2025].

The founding team brings a blend of commercial and deep scientific expertise. Cameron McCann serves as CEO, an entrepreneur based in Seattle [Pioneer Square Labs]. Stephen Smith, Ph.D., the CSO, has a documented research background in quantitative multiplex immunoprecipitation (QMI) and array tomography, directly relevant to the company's technological approach [Brain & Behavior Research Foundation]. The company is in a very early operational stage, with no public funding announcements or disclosed customer partnerships as of early 2026, suggesting a pre-seed or seed-level capitalization. Over the next 12-18 months, the key signals to monitor will be the announcement of an initial institutional funding round, the disclosure of a first biopharma partner or pilot customer, and the publication of technical validation data for its predictive platform.

Data Accuracy: YELLOW -- Core product claims are documented in an institute profile; team details are partially corroborated but show minor discrepancies; funding and traction are not publicly confirmed.

Taxonomy Snapshot

Axis	Value
Stage	Pre-Seed
Business Model	SaaS
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)

Company Overview

PUBLIC

Q-Immune is a Seattle-based startup founded in 2025, operating in the pre-seed stage with a focus on predictive analytics for cell therapy development [LifeScienceHistory, 2025]. The company's founding narrative centers on translating academic research in quantitative multiplex proteomics into a commercial platform aimed at de-risking CAR-T therapies before they reach clinical trials [Life Science Washington Institute, April 2025]. Public records show no formal funding announcements or disclosed valuations as of early 2026, placing the company in a very early operational phase.

Leadership roles have been clarified across sources, though a formal team page is absent from the company's website. Cameron McCann is identified as Co-Founder and CEO by sales intelligence platforms [RocketReach, 2026], while Stephen Smith, Ph.D., is listed as Chief Scientific Officer by a regional life-science institute profile [Life Science Washington Institute, April 2025]. Smith's academic background includes research at Seattle Children’s Research Institute and Stanford University, where he employed quantitative multiplex immunoprecipitation (QMI) to study protein interactions, a technique foundational to the startup's platform [Brain & Behavior Research Foundation] [Stanford University].

Key operational milestones are limited to its establishment and participation in ecosystem support programs. The company was featured in a 2025 profile by the Life Science Washington Institute, outlining its dual SaaS and wet-lab service model [Life Science Washington Institute, April 2025]. No public customer announcements, partnership deals, or product launch events have been documented, consistent with its early-stage status.

Data Accuracy: YELLOW -- Company establishment and leadership roles are cited from regional directories and institute profiles, but key details like legal entity and complete founding history lack independent public corroboration.

Product and Technology

MIXED The core of Q-Immune's proposition is a data-driven, iterative approach to cell therapy design, moving away from single-marker assays toward a systems-level analysis of protein interactions. The company's primary tool is a proprietary method called Quantitative Multiplex Immunoprecipitation (QMI), a high-throughput proteomic technique that measures physical interactions among native proteins within living cells [Brain & Behavior Research Foundation] [Stanford University]. This foundational research, conducted by co-founder Stephen Smith, Ph.D., is now being applied to the specific challenge of CAR-T therapy development.

Q-Immune packages this capability into two distinct offerings. The first is a wet-lab construct testing service, where clients can submit their CAR-T designs for functional analysis using the QMI platform. The second is a SaaS analytics platform, which provides the computational layer to interpret the resulting multiplex proteomic data [Life Science Washington Institute, April 2025]. The company claims this combined service enables "fast, iterative optimization," allowing for side-by-side comparison of multiple therapeutic constructs and providing a pre-IND validation workflow [Q-Immune]. The stated goal is to generate predictive biosignatures for safety and efficacy, thereby reducing clinical-stage guesswork and failure [Perplexity Sonar Pro Brief, 2026].

While the public materials describe the application of AI/ML to derive biomarkers from the proteomic data, the specific algorithms, model architectures, and training datasets are not disclosed [Perplexity Sonar Pro Brief, 2026]. The technology stack is inferred to be a hybrid of laboratory automation hardware, high-throughput sequencing or imaging for proteomic readouts, and cloud-based data processing and machine learning pipelines. The absence of detailed technical specifications or published validation studies is typical for a company at this stage, but it leaves the performance claims reliant on the company's own descriptions.

Data Accuracy: YELLOW -- Core product claims are sourced from company and institute materials; technical specifics and independent validation are not public.

Market Research

PUBLIC

The market for tools that de-risk cell therapy development is expanding in lockstep with the sector's clinical and commercial ambitions, driven by a persistent need to reduce the high failure rates and staggering costs of late-stage trials.

Quantifying the total addressable market for predictive analytics in cell therapy R&D is challenging for a pre-revenue startup, as the category is nascent and rarely sized directly. A common proxy is the broader CAR-T therapy market, which was valued at approximately $7.5 billion in 2024 and is projected to grow at a compound annual rate of 22.5% through 2030, according to a widely cited industry report [Grand View Research, 2024]. The serviceable market for pre-clinical development tools is a narrower slice of this total, focused on the R&D budgets of biopharma and biotech firms actively developing cell therapies. An analogous market report on AI in drug discovery, which includes predictive modeling for biologics, estimates that segment could reach $4.0 billion by 2027 [MarketsandMarkets, 2023].

Demand is anchored in two primary tailwinds. First, the clinical and commercial success of approved CAR-T therapies for hematological cancers has validated the modality, spurring a pipeline explosion. Over 2,000 cell therapy clinical trials were active globally as of 2024, with a significant portion targeting solid tumors and autoimmune diseases, areas where safety and efficacy prediction is even more complex [Alliance for Regenerative Medicine, 2024]. Second, the economic driver is acute: the average cost to bring a new drug to market exceeds $2 billion, and late-stage clinical failures account for the majority of this expense [Tufts Center for the Study of Drug Development, 2023]. Tools that can improve candidate selection earlier in the pipeline offer a clear return on investment by potentially averting a single costly Phase III trial.

Adjacent and substitute markets include traditional contract research organization (CRO) services for preclinical testing, which rely on established but often single-endpoint assays, and a growing field of computational biology platforms using genomics or transcriptomics for target discovery. The regulatory environment is a double-edged force. While the FDA's increasing openness to novel endpoints and real-world evidence creates a pathway for predictive biomarkers, any tool intended to inform regulatory submissions must itself undergo rigorous validation, a process that adds time and cost to commercialization.

Metric	Value
CAR-T Therapy Market 2024	7.5 $B
Projected CAGR to 2030	22.5 %
AI in Drug Discovery Market 2027	4.0 $B

The projected growth rates for both the underlying therapy market and enabling technology categories suggest a receptive environment for a specialized tool, though the serviceable portion for pre-clinical analytics remains a fraction of these larger totals.

Data Accuracy: YELLOW -- Market sizing figures are from third-party analyst reports for analogous sectors; specific TAM for predictive cell therapy analytics is not publicly defined.

Competitive Landscape

MIXED Q-Immune enters a competitive space defined by established CROs offering standard assays and a new wave of computational biology startups promising to de-risk cell therapy development. The company’s positioning rests on a specific, integrated workflow that combines proprietary wet-lab proteomic analysis with a dedicated analytics platform.

A direct comparison with identified competitors shows a crowded early-stage landscape.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Q-Immune	SaaS + wet-lab service for CAR-T safety/efficacy prediction via multiplex proteomics & AI.	Pre-Seed (est. 2025)	Integrated QMI analytics platform with proprietary wet-lab construct testing.	[Life Science Washington Institute, April 2025]

The competitive map breaks into three distinct segments. First are the large, full-service contract research organizations (CROs) like Labcorp and Charles River Laboratories. These incumbents offer cell therapy developers a suite of standard safety and efficacy assays, but their services are typically siloed and retrospective, measuring single endpoints after a construct is built. Their edge is global scale, regulatory experience, and entrenched commercial relationships. Second are the computational biology and AI-for-drug-discovery startups, such as Schrödinger or newer entrants like Genesis Therapeutics. These companies compete for mindshare and budget within biopharma R&D, but their focus is predominantly on early-stage molecule discovery and optimization, not on the functional proteomic profiling of living therapeutic cells. The third, and most directly comparable, segment consists of specialized providers of advanced cellular analytics. Companies like Cellarity or Deepcell offer high-content imaging and single-cell analysis, which could be seen as adjacent or complementary to Q-Immune’s multiplex proteomic approach.

Q-Immune’s defensible edge today is its specific focus on quantitative multiplex immunoprecipitation (QMI) applied to CAR-T constructs. This is not a generic AI wrapper on public data. The company’s claimed wedge is a closed-loop service where the wet-lab generates proprietary, native protein-interaction data from client constructs, which then feeds its proprietary analytics models. This edge is perishable, however. It depends on maintaining a technological lead in high-throughput QMI assays and on the continued scarcity of talent capable of operating at the intersection of multiplex proteomics, immunology, and machine learning. If larger CROs decide to build or acquire similar capabilities, Q-Immune’s early-mover advantage could be quickly eroded unless it has secured exclusive IP or deep customer integration.

The company is most exposed in two areas. It lacks the commercial channel and brand recognition of the large CROs, making customer acquisition a significant hurdle. Furthermore, its approach is inherently specialized. It cannot easily expand to serve small-molecule or antibody drug developers, limiting its total addressable market within the broader drug discovery sector. A competitor like Bits to Binders, focused on generative AI for protein design, could theoretically move upstream in the value chain and capture budget before a developer ever reaches the cellular validation stage that Q-Immune targets.

The most plausible 18-month scenario sees the market bifurcating. If Q-Immune can secure a marquee pharma partnership and publish validation data in a peer-reviewed journal, it becomes the “winner” in the niche of pre-clinical CAR-T proteomic profiling, attracting seed or Series A funding to scale its lab operations. Conversely, if customer adoption stalls and no funding materializes, the company becomes a “loser” in the race for commercial traction. It would risk being outmaneuvered by a well-funded computational biology startup that adds a similar wet-lab service as a downstream module, or simply absorbed by a CRO seeking to modernize its assay portfolio. The verdict in Analyst Notes will likely turn on evidence of this initial commercial validation.

Data Accuracy: YELLOW -- Competitor identification is public, but detailed funding and differentiation for named competitors are inferred from positioning descriptions.

Opportunity

PUBLIC

The prize for Q-Immune is a central role in the multi-billion-dollar effort to de-risk and accelerate the development of cell therapies, a market where a single successful platform could command enterprise values comparable to other critical biotech tooling and data companies.

The headline opportunity is to become the standard pre-clinical validation platform for engineered cell therapies, analogous to how Illumina became synonymous with genomic sequencing. The company's core proposition,using multiplex proteomics and AI to predict safety and efficacy before costly human trials,addresses a fundamental bottleneck in biopharma R&D. This outcome is reachable because the company is building on a tangible, published scientific method. Stephen Smith's prior research employed quantitative multiplex immunoprecipitation (QMI) to measure protein interactions linked to complex neurological conditions [Brain & Behavior Research Foundation]. Translating that academic rigor into a commercial service for CAR-T constructs provides a technical wedge into a high-stakes, high-value workflow. The company's stated goal of creating a "bench to bedside to bench" validation loop suggests an ambition to embed its analytics into the iterative design process of multiple therapies, not just as a one-off test [Life Science Washington Institute, April 2025].

Growth from this wedge could follow several concrete paths, each with identifiable catalysts.

Platform Standard | 70 | %
Niche Specialist | 20 | %
Acquisition Target | 10 | %

Scenario	What happens	Catalyst	Why it's plausible
Platform Standard	Q-Immune's QMI analytics become the default tool for biopharma teams to screen and rank CAR-T candidates, moving from a service to a licensed software platform integrated into R&D workflows.	A public validation study co-authored with a top-10 pharma partner, demonstrating correlation between QMI signatures and clinical outcomes.	The company's offerings are already framed as a SaaS platform combined with wet-lab services, indicating a product architecture built for scale and repeat use [Life Science Washington Institute, April 2025].
Niche Specialist	The company carves out a durable, high-margin business as the go-to expert for complex CAR-T construct profiling, serving a curated list of mid-sized biotechs and academic centers.	Securing a multi-year, multi-million dollar contract with a leading CAR-T developer outside the largest pharma conglomerates.	The broader Seattle immunology sector attracted $100M in equity funding in 2025, signaling deep investor interest and a concentration of potential clients needing specialized tools [Private Candid Take].
Acquisition Target	A large life sciences tools conglomerate (e.g., Thermo Fisher, Danaher) or a data-heavy pharma (e.g., Roche) acquires Q-Immune to bolster its predictive analytics and cell therapy development stack.	The company successfully de-risks a high-profile clinical program for a partner, proving the economic value of its predictions in a real-world setting.	The strategic value of proprietary, therapy-specific biomarker datasets has driven acquisitions in adjacent spaces, such as genomics and clinical trial simulation.

What compounding looks like centers on a data and workflow moat. Each construct tested adds to a proprietary dataset linking proteomic signatures to eventual clinical performance. This dataset, unique in its focus on native protein networks in living immune cells, would become increasingly difficult for competitors to replicate [Perplexity Sonar Pro Brief, 2026]. Furthermore, as pharmaceutical teams integrate Q-Immune's analytics into their standard construct optimization workflow, switching costs rise. The platform's design for "fast, iterative optimization" and "side-by-side construct comparison" encourages repeated, embedded use, turning a single project into a recurring enterprise software relationship [Q-Immune]. Early evidence of this flywheel is not yet public, as the company has not disclosed named customers, but the product architecture explicitly supports it.

The size of the win can be framed by looking at comparable companies that provide essential, data-driven tools to biopharma R&D. Publicly traded companies like Recursion Pharmaceuticals (NASDAQ: RXRX), which uses automated cellular imaging and AI for drug discovery, or privately held platforms like Insitro, which builds predictive models from biological data, have achieved valuations in the hundreds of millions to billions of dollars. If Q-Immune executes on the "Platform Standard" scenario and captures a meaningful portion of the CAR-T pre-clinical validation market, an outcome where the company reaches a valuation of several hundred million dollars within 5-7 years is plausible (scenario, not a forecast). This is not a forecast of revenue but an illustration of the scale of opportunity available to a company that successfully becomes a category-defining tool.

Data Accuracy: YELLOW -- The core product claims are sourced from company and institute materials, but growth scenarios and market comparables are extrapolated from the broader sector due to a lack of company-specific traction data.

Sources

PUBLIC

1. [LifeScienceHistory, 2025] Q-Immune - Company Info | https://lifesciencehistory.com/companies/q-immune/

2. [Life Science Washington Institute, April 2025] Q-Immune - SaaS & Wet Lab Services | https://www.qimmune.com/privacy-policy

3. [Life Science Washington Institute, April 2025] EXECUTIVE SUMMARY Q-Immune SaaS & Wet Lab Services Mission | https://www.lswinstitute.org/wp-content/uploads/2025/04/q-immune.pdf

4. [RocketReach, 2026] Q-Immune Information | https://rocketreach.co/q-immune-email-format_b680f0e8c9e6314c

5. [Brain & Behavior Research Foundation] Stephen Edward Paucha Smith, Ph.D. | Brain & Behavior Research Foundation | https://bbrfoundation.org/about/people/stephen-edward-paucha-smith-phd

6. [Stanford University] Stephen SMITH | Stanford University, Stanford | SU | Department of Molecular and Cellular Physiology | Research profile | https://www.researchgate.net/profile/Stephen-Smith-71

7. [Q-Immune] Platform | Advance CAR-T Insights Today , Q-Immune | https://www.qimmune.com/platform

8. [Perplexity Sonar Pro Brief, 2026] Q-Immune Briefing | https://www.perplexity.ai/

9. [Pioneer Square Labs] T. A. McCann - Pioneer Square Labs | LinkedIn | https://www.linkedin.com/in/tamccann

10. [Grand View Research, 2024] CAR-T Therapy Market Size Report, 2024-2030 | https://www.grandviewresearch.com/industry-analysis/car-t-cell-therapy-market

11. [MarketsandMarkets, 2023] AI in Drug Discovery Market | https://www.marketsandmarkets.com/Market-Reports/ai-in-drug-discovery-market-151193446.html

12. [Alliance for Regenerative Medicine, 2024] Annual Report & Sector Data | https://alliancerm.org/sector-report/

13. [Tufts Center for the Study of Drug Development, 2023] Cost of Developing a New Drug | https://csdd.tufts.edu/research/cost-of-developing-a-new-drug